{"preliminary_commentary":{"by_channel":{"youtube":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["futibatinib","pembrolizumab"]],"indication":"advanced or metastatic urothelial carcinoma","name":"NCT04601857","nct_id":"NCT04601857","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04601857. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with metastatic urothelial carcinoma (UC) and FGFR3 mutation or FGFR1-4 fusion/rearrangement received futibatinib 20 milligrams (mg), orally, once daily (QD), in a 21-day cycle for maximum duration of 590 days along with pembrolizumab 200 mg, intravenously (IV), every 3 weeks (Q3W), in a 21-day cycle for a maximum of 35 doses or a maximum duration of 2 years.","label":"Cohort A","type":"EXPERIMENTAL"},{"description":"Participants with metastatic UC (including participants with other FGFR or non-FGFR genetic aberrations and participants with wild type \\[non-mutated\\] tumors) received futibatinib 20 mg, orally, QD, in a 21-day cycle for maximum duration of 563 days along with pembrolizumab 200 mg, IV, Q3W in a 21-day cycle for a maximum of 35 doses or a maximum duration of 2 years.","label":"Cohort B","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2025-09-16","type":"ACTUAL"},"conditions":["Advanced and Metastatic Urothelial Cancer"],"enrollment":{"count":43,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Futibatinib","otherNames":["TAS120"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["KEYTRUDA","MK-3475-B04"],"type":"DRUG"}],"last_update":"2025-12-31","lead_sponsor":"Taiho Oncology, Inc.","official_title":"A Phase 2 Study Evaluating Futibatinib (TAS 120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-03-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR)","timeFrame":"Up to 38 months"}],"references":[],"start_date":{"date":"2021-01-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma","url":"https://clinicaltrials.gov/study/NCT04601857"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04601857"}